Entero Healthcare Solutions Limited has informed the Exchange about Investor Presentation
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare reported strong FY26 results with revenue of Rs 6,591 Cr, up 29.3% YoY, and Q4FY26 revenue of Rs 1,910 Cr up 42.6% YoY. Like-for-like growth was 31.5% for FY26 and 43.1% for Q4FY26, significantly outpacing industry growth of 10%. EBITDA margin expanded to 4.0% in FY26 (from 3.4% last year) and 4.5% in Q4FY26. The company turned cashflow positive with operating cashflow of Rs 96.2 Cr in FY26 versus negative Rs 76.9 Cr in FY25. ROCE improved to 14.6% from 10.7%. Seven acquisitions were closed during FY26, with MedTech segment expected to exceed Rs 1,000 Cr revenue in FY27. FY27 guidance targets 23% revenue growth, 5.0% EBITDA margin, and 50% operating cashflow to EBITDA conversion.
The company delivered on all FY26 guidance metrics and shows strong momentum in margin expansion and cash generation. The improvement from loss-making operations three years ago to Rs 96 Cr positive operating cashflow demonstrates successful execution of the consolidation strategy. The MedTech expansion and guidance for continued margin improvement are positive signals for shareholders.